Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15375MR)

This product GTTS-WQ15375MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15375MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6802MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ2294MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ10678MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ1660MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ12013MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ2570MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ9406MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ7959MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW